{"id":1558,"date":"2024-06-04T10:24:00","date_gmt":"2024-06-04T02:24:00","guid":{"rendered":"https:\/\/vcro.online\/?p=1558"},"modified":"2024-07-15T15:44:39","modified_gmt":"2024-07-15T07:44:39","slug":"congratulations-allogeneic-mesenchymal-stem-cells-for-pre-frailty-frailty-treatment-has-received-tfda-approval-for-phase-i-ii-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.vcro.com.tw\/?p=1558","title":{"rendered":"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial!"},"content":{"rendered":"\n

In February 2024, the professional team from VCRO assisted the client in submitting an allogeneic mesenchymal stem cell product for clinical trials in the field of frailty to TFDA. The team successfully obtained TFDA approval to proceed with Phase I\/II clinical trials, helping the client smoothly transition to the clinical trial phase.<\/p>\n\n\n

\"\"<\/figure>","protected":false},"excerpt":{"rendered":"

In February 2024, the professional team from VCRO assisted the client in submitting an allogeneic mesenchymal stem cell product for clinical trials in the field of frailty to TFDA. The team successfully obtained TFDA approval to proceed with Phase I\/II clinical trials, helping the client smoothly transition to the clinical trial phase.<\/p>\n","protected":false},"author":1,"featured_media":1713,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-1558","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-vcro-express"],"yoast_head":"\r\nCongratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial! - VCRO<\/title>\r\n<meta name=\"description\" content=\"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial! VCRO -\" \/>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/www.vcro.com.tw\/?p=1558\" \/>\r\n<meta property=\"og:locale\" content=\"en_US\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial! - VCRO\" \/>\r\n<meta property=\"og:description\" content=\"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial! VCRO -\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/www.vcro.com.tw\/?p=1558\" \/>\r\n<meta property=\"og:site_name\" content=\"VCRO\" \/>\r\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/people\/\/100057388670681\/\" \/>\r\n<meta property=\"article:published_time\" content=\"2024-06-04T02:24:00+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2024-07-15T07:44:39+00:00\" \/>\r\n<meta property=\"og:image\" content=\"https:\/\/www.vcro.com.tw\/wp-content\/uploads\/2024\/06\/5cc3eda3-9bc8-49b1-bb84-ebf6e32765c7.jpg\" \/>\r\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\r\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\r\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\r\n<meta name=\"author\" content=\"VCRO\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"VCRO\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1558#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1558\"},\"author\":{\"name\":\"VCRO\",\"@id\":\"https:\/\/www.vcro.com.tw\/#\/schema\/person\/2f08cc59b04b0a3bd4c58d32eb630c43\"},\"headline\":\"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial!\",\"datePublished\":\"2024-06-04T02:24:00+00:00\",\"dateModified\":\"2024-07-15T07:44:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1558\"},\"wordCount\":78,\"publisher\":{\"@id\":\"https:\/\/www.vcro.com.tw\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1558#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.vcro.com.tw\/wp-content\/uploads\/2024\/06\/5cc3eda3-9bc8-49b1-bb84-ebf6e32765c7.jpg\",\"articleSection\":[\"VCRO express\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1558\",\"url\":\"https:\/\/www.vcro.com.tw\/?p=1558\",\"name\":\"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial! - VCRO\",\"isPartOf\":{\"@id\":\"https:\/\/www.vcro.com.tw\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1558#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1558#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.vcro.com.tw\/wp-content\/uploads\/2024\/06\/5cc3eda3-9bc8-49b1-bb84-ebf6e32765c7.jpg\",\"datePublished\":\"2024-06-04T02:24:00+00:00\",\"dateModified\":\"2024-07-15T07:44:39+00:00\",\"description\":\"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial! VCRO -\",\"breadcrumb\":{\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1558#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.vcro.com.tw\/?p=1558\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1558#primaryimage\",\"url\":\"https:\/\/www.vcro.com.tw\/wp-content\/uploads\/2024\/06\/5cc3eda3-9bc8-49b1-bb84-ebf6e32765c7.jpg\",\"contentUrl\":\"https:\/\/www.vcro.com.tw\/wp-content\/uploads\/2024\/06\/5cc3eda3-9bc8-49b1-bb84-ebf6e32765c7.jpg\",\"width\":1024,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1558#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.vcro.com.tw\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.vcro.com.tw\/#website\",\"url\":\"https:\/\/www.vcro.com.tw\/\",\"name\":\"VCRO - Asia Pacific CRO Based in Taiwan\",\"description\":\"Virginia Contract Research Organization Co., Ltd.- Asia Pacific CRO Based in Taiwan\",\"publisher\":{\"@id\":\"https:\/\/www.vcro.com.tw\/#organization\"},\"alternateName\":\"VCRO\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.vcro.com.tw\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.vcro.com.tw\/#organization\",\"name\":\"Virginia Contract Research Organization Co., Ltd.\",\"alternateName\":\"VCRO\",\"url\":\"https:\/\/www.vcro.com.tw\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.vcro.com.tw\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/vcro.com.cn\/wp-content\/uploads\/2024\/07\/VCRO-logo-512-512-background-transparent.png\",\"contentUrl\":\"https:\/\/vcro.com.cn\/wp-content\/uploads\/2024\/07\/VCRO-logo-512-512-background-transparent.png\",\"width\":512,\"height\":512,\"caption\":\"Virginia Contract Research Organization Co., Ltd.\"},\"image\":{\"@id\":\"https:\/\/www.vcro.com.tw\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/people\/\/100057388670681\/\",\"https:\/\/line.me\/R\/ti\/p\/277jsobo\",\"http:\/\/weixin.qq.com\/r\/eRD64tPE0I6vrZeB90Vr\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.vcro.com.tw\/#\/schema\/person\/2f08cc59b04b0a3bd4c58d32eb630c43\",\"name\":\"VCRO\",\"sameAs\":[\"https:\/\/www.vcro.com.tw\"],\"url\":\"https:\/\/www.vcro.com.tw\/?author=1\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial! - VCRO","description":"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial! VCRO -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.vcro.com.tw\/?p=1558","og_locale":"en_US","og_type":"article","og_title":"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial! - VCRO","og_description":"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial! VCRO -","og_url":"https:\/\/www.vcro.com.tw\/?p=1558","og_site_name":"VCRO","article_publisher":"https:\/\/www.facebook.com\/people\/\/100057388670681\/","article_published_time":"2024-06-04T02:24:00+00:00","article_modified_time":"2024-07-15T07:44:39+00:00","og_image":[{"width":1024,"height":1024,"url":"https:\/\/www.vcro.com.tw\/wp-content\/uploads\/2024\/06\/5cc3eda3-9bc8-49b1-bb84-ebf6e32765c7.jpg","type":"image\/jpeg"}],"author":"VCRO","twitter_card":"summary_large_image","twitter_misc":{"Written by":"VCRO"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.vcro.com.tw\/?p=1558#article","isPartOf":{"@id":"https:\/\/www.vcro.com.tw\/?p=1558"},"author":{"name":"VCRO","@id":"https:\/\/www.vcro.com.tw\/#\/schema\/person\/2f08cc59b04b0a3bd4c58d32eb630c43"},"headline":"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial!","datePublished":"2024-06-04T02:24:00+00:00","dateModified":"2024-07-15T07:44:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.vcro.com.tw\/?p=1558"},"wordCount":78,"publisher":{"@id":"https:\/\/www.vcro.com.tw\/#organization"},"image":{"@id":"https:\/\/www.vcro.com.tw\/?p=1558#primaryimage"},"thumbnailUrl":"https:\/\/www.vcro.com.tw\/wp-content\/uploads\/2024\/06\/5cc3eda3-9bc8-49b1-bb84-ebf6e32765c7.jpg","articleSection":["VCRO express"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.vcro.com.tw\/?p=1558","url":"https:\/\/www.vcro.com.tw\/?p=1558","name":"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial! - VCRO","isPartOf":{"@id":"https:\/\/www.vcro.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.vcro.com.tw\/?p=1558#primaryimage"},"image":{"@id":"https:\/\/www.vcro.com.tw\/?p=1558#primaryimage"},"thumbnailUrl":"https:\/\/www.vcro.com.tw\/wp-content\/uploads\/2024\/06\/5cc3eda3-9bc8-49b1-bb84-ebf6e32765c7.jpg","datePublished":"2024-06-04T02:24:00+00:00","dateModified":"2024-07-15T07:44:39+00:00","description":"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial! VCRO -","breadcrumb":{"@id":"https:\/\/www.vcro.com.tw\/?p=1558#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.vcro.com.tw\/?p=1558"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.vcro.com.tw\/?p=1558#primaryimage","url":"https:\/\/www.vcro.com.tw\/wp-content\/uploads\/2024\/06\/5cc3eda3-9bc8-49b1-bb84-ebf6e32765c7.jpg","contentUrl":"https:\/\/www.vcro.com.tw\/wp-content\/uploads\/2024\/06\/5cc3eda3-9bc8-49b1-bb84-ebf6e32765c7.jpg","width":1024,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/www.vcro.com.tw\/?p=1558#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.vcro.com.tw\/"},{"@type":"ListItem","position":2,"name":"Congratulations! Allogeneic mesenchymal stem cells for pre-frailty & frailty treatment has received TFDA approval for Phase I\/II clinical trial!"}]},{"@type":"WebSite","@id":"https:\/\/www.vcro.com.tw\/#website","url":"https:\/\/www.vcro.com.tw\/","name":"VCRO - Asia Pacific CRO Based in Taiwan","description":"Virginia Contract Research Organization Co., Ltd.- Asia Pacific CRO Based in Taiwan","publisher":{"@id":"https:\/\/www.vcro.com.tw\/#organization"},"alternateName":"VCRO","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.vcro.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.vcro.com.tw\/#organization","name":"Virginia Contract Research Organization Co., Ltd.","alternateName":"VCRO","url":"https:\/\/www.vcro.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.vcro.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/vcro.com.cn\/wp-content\/uploads\/2024\/07\/VCRO-logo-512-512-background-transparent.png","contentUrl":"https:\/\/vcro.com.cn\/wp-content\/uploads\/2024\/07\/VCRO-logo-512-512-background-transparent.png","width":512,"height":512,"caption":"Virginia Contract Research Organization Co., Ltd."},"image":{"@id":"https:\/\/www.vcro.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/people\/\/100057388670681\/","https:\/\/line.me\/R\/ti\/p\/277jsobo","http:\/\/weixin.qq.com\/r\/eRD64tPE0I6vrZeB90Vr"]},{"@type":"Person","@id":"https:\/\/www.vcro.com.tw\/#\/schema\/person\/2f08cc59b04b0a3bd4c58d32eb630c43","name":"VCRO","sameAs":["https:\/\/www.vcro.com.tw"],"url":"https:\/\/www.vcro.com.tw\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/1558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1558"}],"version-history":[{"count":2,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/1558\/revisions"}],"predecessor-version":[{"id":1715,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/1558\/revisions\/1715"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/media\/1713"}],"wp:attachment":[{"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}